Evidence map›Paper›PMID 40600744›Full record

Observational studyJournal of the European Academy of Dermatology and Venereology : JEADV2025

Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups.

Sonja Ständer, Emma Guttman-Yassky, Gil Yosipovitch, Henning Wiegmann, Dieter Metze, Madeline Kim, Ester Del Duca, Kent Bondensgaard, John F Paolini, LOTUS‐PN Investigators Group

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026
    Review
  2. Article
  3. Th2 mRNA gene expression analysis separates Prurigo nodularis into two immune signature groups.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sonja StänderPruritus Medicine Section, Department of Dermatology, and Center for Chronic Pruritus (KCP), University Hospital of Münster, Münster, Germany.ORCID https://orcid.org/0000-0003-3612-7786
Emma Guttman-YasskyDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.ORCID https://orcid.org/0000-0002-9363-324X
Gil YosipovitchDr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.ORCID https://orcid.org/0000-0001-6303-1822
Henning WiegmannPruritus Medicine Section, Department of Dermatology, and Center for Chronic Pruritus (KCP), University Hospital of Münster, Münster, Germany.ORCID https://orcid.org/0000-0001-6289-8600
Dieter MetzePruritus Medicine Section, Department of Dermatology, and Center for Chronic Pruritus (KCP), University Hospital of Münster, Münster, Germany.ORCID https://orcid.org/0000-0002-8058-6683
Madeline KimDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.ORCID https://orcid.org/0000-0002-8108-3631
Ester Del DucaDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.ORCID https://orcid.org/0000-0001-7948-8536
Kent BondensgaardKiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA.ORCID https://orcid.org/0000-0002-1490-468X
John F PaoliniKiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA.ORCID https://orcid.org/0000-0001-7622-8851
LOTUS‐PN Investigators Group

Funding

Kiniksa Pharmaceuticals
6 · The paper itself

Abstract

BACKGROUND AND

objectivesPrurigo nodularis (PN) is a severe, intensely pruritic subtype of chronic prurigo for which the molecular basis and interplay between pathophysiologic mechanisms and clinical manifestations are poorly understood.

methodsLOTUS-PN was a longitudinal observational study that included 54 participants from 11 centers and was designed to improve disease understanding. Protein expression, histology and RNA analyses were performed.

resultsHistologically, all patients had typical PN characteristics. Immunohistochemically, and on the mRNA level, expression in lesional versus non-lesional samples for IL-31 (p < 0.01) was significantly higher. In addition, immunohistochemistry showed higher expression of IL-31RA (p < 0.05), OSM (p < 0.05) and OSMRß (p < 0.01). PN lesional skin showed higher expression of Th2 and Th17/Th22 pathway markers. A correlation analysis of gene expression highlighted two groups of intra-marker correlations dividing the Th2 markers, the first containing barrier and regulatory genes and the other containing markers of general inflammation that correlated negatively and positively with Th17/Th22 genes, respectively. Correlations between gene expression and NRS scores were weak and involved genes associated with general inflammation (MMP12) and Th2 (IL10, CCL18, IL4R).

conclusionsOur study confirms the role of Th2 signature in PN and the dominant role of IL31. Correlation analysis of gene expression showed differing relationships between subsets of the Th2 axis with Th1 and Th17/Th22 markers, highlighting the potential of different components of the Th2 pathway to interact with and modulate other immune axes.

Indexed as

PrurigoRNA, MessengerTh2 CellsAdultAgedFemaleHumansInterleukinsLongitudinal StudiesMaleMiddle AgedOncostatin M Receptor beta SubunitReceptors, InterleukinTh17 CellsIL31 protein, humanIL31RA protein, humanInterleukinsOncostatin M Receptor beta SubunitReceptors, InterleukinRNA, Messengerchronic prurigoneuroimmune itch pathwaysOSMR pathwayprurigo nodularispruritus

Identifiers

PMID40600744
PMCPMC12466102

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.